Hepion Pharmaceuticals(HEPA.US)

Last Updated 19:00:00 ET
longbridge loading

Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
HEPA
+3.64%
Earnings Watch·
US
HEPA
+3.64%

Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake

TradingView·
US
HEPA
+3.64%
US
LABU
+2.38%
US
IBB
+0.76%
TradingView·
US
HEPA
+3.64%
US
LABU
+2.38%
US
IBB
+0.76%

Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04

TradingView·
US
HEPA
+3.64%
US
FBT
+0.77%
US
XLV
+0.66%
TradingView·
US
HEPA
+3.64%
US
FBT
+0.77%
US
XLV
+0.66%

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock News

StockTitan·
US
HELP
+6.45%
StockTitan·
US
HELP
+6.45%

Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net Loss

TradingView·
US
BIB
+0.08%
US
XLV
+0.66%
US
IHE
+1.13%
TradingView·
US
BIB
+0.08%
US
XLV
+0.66%
US
IHE
+1.13%

Hepion Pharmaceuticals | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
HEPA
+3.64%
Earnings Watch·
US
HEPA
+3.64%
© 2026 Longbridge｜Disclaimer